SGLT2 Inhibition in Heart Failure: New Updates
Published: 08 February 2023
-
Views:
10302
-
Likes:
7
-
Views:
10302
-
Likes:
7
-
Up Next
-
10m 28s
-
13m 27s
-
11m 47s
-
20m 13s
-
12m 35sPart 10 Panel Discussion
-
29m 31sPart 1 Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors? John JV McMurray
-
10m 53sPart 2 SGLT2 Inhibition in the Elderly and Frail Patients Pardeep Jhund
-
9m 34sPart 3 Gender Differences in Outcomes With SGLT2 Inhibitors Xiaowen “Wendy” Wang
-
10m 55sPart 4 Efficacy and Safety of SGLT2 Inhibitors in Black Patients Subodh Verma
Overview
This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.
Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
Learning Objectives
- To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
- To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
- To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
- To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
- To assess the merit of ejection fraction in heart failure care
Target Audience
- Primary Care Physicians
- Endocrinologists
- Nephrologists
- Cardiologists
- Nurses
- Pharmacists
- Dietitians
- Diabetes Educators
More from this programme
Part 1
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?
Part 2
SGLT2 Inhibition in the Elderly and Frail Patients
Part 3
Gender Differences in Outcomes With SGLT2 Inhibitors
Part 4
Efficacy and Safety of SGLT2 Inhibitors in Black Patients
Part 5
Panel Discussion
| 1 session | |
| Panel Discussion | Watch now |
Part 6
SGLT2 Inhibition in Patients With Improved EF
Part 7
SGLT2 Inhibition With MRAs and ARNis
Part 8
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?
Part 9
Does EF Still Matter in HF Management?
Part 10
Panel Discussion
| 1 session | |
| Panel Discussion | Watch now |
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Subodh Verma
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.
Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.
John JV McMurray
Professor of Cardiology
Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.
Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.
Pardeep Jhund
Reader in Cardiology, University of Glasgow
Dr Pardeep Jhund is a Reader in Cardiology at the University of Glasgow, UK.
He Trained in medicine at the University of Glasgow, and completed his general medical training in Edinburgh. During this time he also graduated with a MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, London, UK.
Prior to this, he graduated from the University of Glasgow with a PhD in cardiovascular epidemiology, under the tutelage of Prof John McMurray, and completed his fellowship at The Brigham and Women’s Hospital, Boston, US.
Dr Jhund has a special interest in heart failure, around which he has published widely in leading international journals.